Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome

被引:66
|
作者
Meintjes, Graeme [1 ,4 ,5 ]
Skolimowska, Keira H.
Wilkinson, Katalin A. [6 ]
Matthews, Kerryn
Tadokera, Rebecca
Conesa-Botella, Anali [7 ,8 ]
Seldon, Ronnett
Rangaka, Molebogeng X.
Rebe, Kevin [4 ]
Pepper, Dominique J.
Morroni, Chelsea [2 ]
Colebunders, Robert [7 ,8 ]
Maartens, Gary [3 ]
Wilkinson, Robert J. [4 ,5 ,6 ]
机构
[1] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, ZA-7925 Cape Town, South Africa
[2] Univ Cape Town, Sch Publ Hlth & Family Med, Womens Hlth Res Unit, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[4] GF Jooste Hosp, Cape Town, South Africa
[5] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
[6] Natl Inst Med Res, London NW7 1AA, England
[7] Univ Antwerp, Inst Trop Med, Dept Clin Sci, B-2020 Antwerp, Belgium
[8] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium
基金
英国惠康基金; 英国医学研究理事会;
关键词
human immunodeficiency virus; tuberculosis; immune reconstitution; inflammatory syndrome; glucocorticoids; HIV-INFECTED ADULTS; MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; ANTIRETROVIRAL THERAPY; CASE DEFINITIONS; CLINICAL-TRIAL; DISEASE; PREDNISOLONE; MENINGITIS; DEXAMETHASONE;
D O I
10.1164/rccm.201201-0094OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: HIV-tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an immunopathological reaction to mycobacterial antigens induced by antiretroviral therapy. Prednisone reduces morbidity in TB-IRIS, but the mechanisms are unclear. Objectives: To determine the effect of prednisone on the inflammatory response in TB-IRIS (antigen-specific effector T cells, cytokines, and chemokines). Methods: Blood was taken from participants in a randomized placebo-controlled trial of prednisone for TB-IRIS, at 0, 2, and 4 weeks. Participants received prednisone at a dosage of 1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks, or placebo at identical dosages. Measurements and Main Results: Analyses included IFN-gamma enzyme-linked immunospot (ELISPOT), reverse transcription-polymerase chain reaction on peripheral blood mononuclear cells after restimulation with heat-killed Mycobacterium tuberculosis, Luminex multiplex cytokine analysis of corresponding tissue culture supernatants, and Luminex multiplex cytokine analysis of serum. Fifty-eight participants with TB-IRIS (31 receiving prednisone, 27 receiving placebo) were included. In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-alpha, IFN-gamma, and IFN-gamma-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. No differences in ELISPOT responses comparing prednisone and placebo groups were shown in response to ESAT-6 (early secreted antigen target-6), Acr1, Acr2, 38-kD antigen, or heat-killed H37Rv M. tuberculosis. Purified protein derivative ELISPOT responses increased over 4 weeks in the prednisone group and decreased in the placebo group (P = 0.007). Conclusions: The beneficial effects of prednisone in TB-IRIS appear to be mediated via suppression of predominantly proinflammatory cytokine responses of innate immune origin, not via a reduction of the numbers of antigen-specific T cells in peripheral blood.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 50 条
  • [1] Tuberculosis-immune Reconstitution Inflammatory Syndrome
    Hamada, Satoshi
    Adachi, Yoshihiko
    INTERNAL MEDICINE, 2020, 59 (03) : 459 - 460
  • [2] Immune Reconstitution Inflammatory Syndrome in CNS Tuberculosis
    Elizabeth, K. E.
    Jubin, K.
    INDIAN PEDIATRICS, 2014, 51 (08) : 668 - 668
  • [3] The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome
    Lai, Rachel P. J.
    Nakiwala, Justine K.
    Meintjes, Graeme
    Wilkinson, Robert J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2013, 43 (08) : 1995 - 2002
  • [4] Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis
    Bell, Lucy C. K.
    Breen, Ronan
    Miller, Robert F.
    Noursadeghi, Mahdad
    Lipman, Marc
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 32 : 39 - 45
  • [5] Aberrant Inflammasome Activation Characterizes Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
    Tan, Hong Yien
    Yong, Yean Kong
    Shankar, Esaki M.
    Paukovics, Geza
    Ellegard, Rada
    Larsson, Marie
    Kamarulzaman, Adeeba
    French, Martyn A.
    Crowe, Suzanne M.
    JOURNAL OF IMMUNOLOGY, 2016, 196 (10): : 4052 - 4063
  • [6] Tuberculosis and immune reconstitution inflammatory syndrome. Pediatric case
    Bustos, Ana C.
    Zarate, Gabriela M.
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2020, 118 (01): : E39 - E42
  • [7] Unmasked Tuberculosis with Immune Reconstitution Inflammatory Syndrome; Where Is It Hiding?
    Ahsan, M.
    Nair, A. Sreekantan
    Ranjha, F.
    Fless, K.
    Raju, P., I
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [8] A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome
    Silva, Carlos A. M.
    Graham, Barbara
    Webb, Kristofor
    Ashton, Laura Vari
    Harton, Marisa
    Luetkemeyer, Annie F.
    Bokatzian, Samantha
    Almubarak, Reem
    Mahapatra, Sebabrata
    Hovind, Laura
    Kendall, Michelle A.
    Havlir, Diane
    Belisle, John T.
    De Groote, Mary Ann
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 84 : 30 - 38
  • [9] Tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS)
    Breton, G.
    JOURNAL DES ANTI-INFECTIEUX, 2012, 14 (04) : 180 - 185
  • [10] Urinary Lipoarabinomannan as Predictor for the Tuberculosis Immune Reconstitution Inflammatory Syndrome
    Conesa-Botella, Anali
    Loembe, Marguerite Massinga
    Manabe, Yukari C.
    Worodria, William
    Mazakpwe, Doreen
    Luzinda, Kenneth
    Mayanja-Kizza, Harriet
    Miri, Mitra
    Mbabazi, Olive
    Koole, Olivier
    Kestens, Luc
    Colebunders, Robert
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (05) : 463 - 468